Biotech

All Articles

AstraZeneca articles information on internal rivals to AbbVie, Pfizer ADCs

.AstraZeneca has discussed an early look at the performance of its in-house antibody-drug conjugate ...

iTeos- GSK's TIGIT star presents meaningful renovation

.After announcing a stage 3 launch based on positive midstage end results, iTeos and GSK are actuall...

More joint FDA can speed up unusual disease R&ampD: report

.The FDA should be even more open and also collaborative to discharge a rise in approvals of unusual...

Zenas, MBX, Bicara scalp to Nasdaq in very hot time for biotech IPOs

.It's an extraordinarily hectic Friday for biotech IPOs, with Zenas BioPharma, MBX as well as Bicara...

Atea's COVID antiviral stops working to halt hospital stays in period 3

.Atea Pharmaceuticals' antiviral has stopped working yet another COVID-19 trial, yet the biotech sti...

Neurocrine's proposal to conserve schizophrenia possibility fails

.Neurocrine Biosciences' mental illness program pivot has actually stopped working. The biotech was ...

Sanofi pays for $110M upfront for late-stage radioligand treatment

.Sanofi has actually made a late entrance to the radioligand celebration, spending one hundred thous...

F 2G rears $100M for 2nd effort to receive brand-new antifungal to market

.After F2G's initial attempt to acquire a brand-new training class of antifungal to market was hinde...

Moderna targets $1.1 B in R&ampD costs cuts, drops 5 programs among earnings pressures

.Moderna has actually pledged to reduce R&ampD investing by $1.1 billion through 2027. The decision ...

Sanofi's $80M bank on Pivot dystrophy medicine ends in phase 3 go bust

.Only 4 months after Sanofi wager $80 million in ahead of time cash money on Key Therapeutics' losma...